Arbutus Biopharma
700 Veterans Circle
Warminster
PA
18974
United States
Tel: 267-469-0914
Website: http://www.arbutusbio.com/
Email: ir@arbutusbio.com
442 articles about Arbutus Biopharma
-
Arbutus to Participate in September 2022 Investor Conferences
9/6/2022
Arbutus Biopharma Corporation announced that the Company will participate in the following upcoming investor conferences taking place in New York.
-
Arbutus Biopharma Announces Issuance of a New Key U.S. Patent Related to AB-729
8/30/2022
Arbutus Biopharma Corporation today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,427,823, which provides composition of matter patent protection for Arbutus’ AB-729 RNAi therapeutic product.
-
Arbutus Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8/4/2022
Arbutus Biopharma Corporation today reports its second quarter 2022 financial results and provides corporate updates.
-
Arbutus to Report Second Quarter 2022 Financial Results and Provide Corporate Update
7/21/2022
Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its second quarter 2022 financial results and corporate update for Thursday, August 4, 2022.
-
Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update
6/25/2022
Arbutus Biopharma Corporation announced the presentation of new clinical and pre-clinical data from its proprietary compounds at the European Association for the Study of the Liver International Liver Congress™.
-
Arbutus to Present Seven Scientific Posters at EASL International Liver Congress™ 2022
6/8/2022
Arbutus Biopharma Corporation announced that seven abstracts have been accepted for poster presentations at the European Association for the Study of the Liver International Liver Congress™ 2022 taking place June 22 - 26, 2022 in London, UK.
-
Arbutus to Participate in June Investor Conferences
6/2/2022
Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Company will participate in the following upcoming investor conferences taking place in New York.
-
Antios Therapeutics received a clinical hold on its Hepatitis B virus (HBV) combinatorial therapy from the U.S. Food and Drug Administration on Wednesday.
-
Monday, Moderna told a Delaware federal court that it was immune from patent-infringement charges over the COVID-19 vaccine because it supplied the vaccine for a U.S. government effort.
-
Arbutus to Present at H.C. Wainwright Global Investment Conference
5/17/2022
Arbutus Biopharma Corporation announced that William Collier, Arbutus’ President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022, at 11:30 am ET in Miami, FL.
-
Moderna is still fending off patent challenges over the lipid nanoparticle delivery system used in its COVID-19 vaccine.
-
Arbutus Reports First Quarter 2022 Financial Results and Provides Corporate Update
5/5/2022
Arbutus Biopharma Corporation today reports its first quarter 2022 financial results and provides pipeline updates.
-
Arbutus to Report First Quarter 2022 Financial Results and Provide Corporate Update
4/21/2022
Arbutus Biopharma Corporation today announced that it has scheduled its first quarter 2022 financial results and corporate update for Thursday, May 5, 2022.
-
Who is to thank for the COVID vaccine? Many major biopharma companies are asking that question after a series of lawsuits over patent rights to the vaccine and its associated technology.
-
Arbutus Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update
3/3/2022
Arbutus Biopharma Corporation today reports its fourth quarter and year end 2021 financial results and provides pipeline updates.
-
On Monday, Arbutus and Genevant filed a lawsuit against Moderna challenging patent infringement.
-
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Moderna
2/28/2022
Arbutus Biopharma Corporation and Genevant Sciences today filed a lawsuit in the U.S. District Court for the District of Delaware against Moderna, Inc.
-
Arbutus to Report Fourth Quarter and Year End 2021 Financial Results and Provide Corporate Update
2/17/2022
Arbutus Biopharma Corporation today announced that it has scheduled its fourth quarter and year end 2021 financial results and corporate update for Thursday, March 3, 2022.
-
Arbutus Announces 2022 Corporate Objectives and Provides Financial Update
1/24/2022
Arbutus Biopharma Corporation today announced its 2022 corporate objectives and provided a financial update.
-
Arbutus to Participate at H.C. Wainwright Bioconnect Virtual Conference
1/4/2022
Arbutus Biopharma Corporation announced that the Company will participate in a virtual fireside chat at the H.C. Wainwright Bioconnect Virtual Conference taking place January 10 - 13, 2022.